Stryker (SYK) closed at $325.87 on November 6, 2026, down 2.7% from the previous close, on volume of 3,293,562 shares (30-day average 2,751,545).
Data as of November 6, 2026.
6-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 29, 2026 | Call with Delta Hedge | 20-Nov-26 310 C +300,000 Stock | 5,265 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 6, 2026. See the 10 largest for 30, 60 and 90 days
Stryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS
PRNewswire (Fri, 30-Oct 1:39 PM ET)
Stryker posts 7.7% organic sales growth, but says Q3 fell short of expectations
Market Chameleon (Fri, 30-Oct 7:05 AM ET)
Stryker reports third quarter 2026 operating results
Globe Newswire (Thu, 29-Oct 4:05 PM ET)
Stryker to participate in the 2026 Jefferies Global Healthcare Conference
Globe Newswire (Tue, 27-Oct 8:00 AM ET)
Stryker completes acquisition of ZuriMED to enhance its shoulder offering
Globe Newswire (Mon, 26-Oct 8:00 AM ET)
Globe Newswire (Thu, 15-Oct 11:00 AM ET)
Globe Newswire (Thu, 15-Oct 9:00 AM ET)
Globe Newswire (Wed, 14-Oct 5:12 PM ET)
Stryker launches Sonopet 3, delivering greater power and precision in ultrasonic tissue removal
PRNewswire (Wed, 14-Oct 9:03 AM ET)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Stryker Corp. - SYK
Globe Newswire (Tue, 13-Oct 6:08 PM ET)
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, mechanical thrombectomy systems, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
Stryker trades on the NYSE stock market under the symbol SYK.
As of November 6, 2026, SYK stock price declined to $325.87 with 3,293,562 million shares trading.
SYK has a beta of 0.10, meaning it tends to be less sensitive to market movements. SYK has a correlation of 0.00 to the broad based SPY ETF.
SYK has a market cap of $124.71 billion. This is considered a Large Cap stock.
Last quarter Stryker reported $7 billion in Revenue and $3.52 earnings per share. This fell short of revenue expectation by $-90 million and missed earnings estimates by -$.03.
In the last 3 years, SYK traded as high as $406.19 and as low as $266.93.
The top ETF exchange traded funds that SYK belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
SYK has underperformed the market in the last year with a return of -6.9%, while SPY returned +10.8%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SYK shares. However, SYK has outperformed the market in the last 3 month and 2 week periods, returning -3.2% and +6.1%, while SPY returned -4.1% and -3.2%, respectively. This indicates SYK has been having a stronger performance recently.
SYK support price is $326.98 and resistance is $343.18 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SYK shares will trade within this expected range on the day.
